Lisata and GATC Initiate AI Collaboration to Enhance Drug Development

Lisata Therapeutics, a pharmaceutical company focused on innovative treatments for advanced solid tumors, and GATC Health Corp, renowned for its AI-driven drug discovery, have entered the first phase of a strategic collaboration. This partnership aims to combine Lisata's proficiency in drug development with GATC’s cutting-edge AI technology to streamline and enhance the drug development process.

At the heart of this collaboration is GATC’s Multiomics Advanced Technology™ (MAT) platform, which uses artificial intelligence to evaluate complex biological interactions, predict drug safety and efficacy, and forecast clinical trial outcomes. Initially, this platform will thoroughly analyze Lisata’s investigational drug, certepetide, to identify optimal development pathways and reduce risks associated with its progression through clinical phases. This analysis will focus on determining the best strategies for certepetide’s Phase 3 development in metastatic pancreatic ductal adenocarcinoma and exploring additional potential indications.

The partnership also envisions identifying combination therapies involving certepetide across various medical fields, including areas beyond oncology. As the collaboration unfolds, Lisata will serve as an operational partner for GATC, leveraging its expertise to advance GATC's own drug candidates toward clinical trials. GATC’s MAT AI has already facilitated the discovery of new drugs targeting conditions such as addiction, PTSD, diabetes, obesity, and cognitive decline, demonstrating its transformative potential.

This collaboration is set to significantly mitigate the inherent risks and substantial costs traditionally associated with drug development. By employing GATC’s AI platform, the partners anticipate identifying drug candidates with a higher likelihood of success, thereby enabling more focused research and shorter development timelines. This approach is expected to improve capital management while accelerating the availability of innovative treatments.

David J. Mazzo, CEO of Lisata, expressed enthusiasm for the partnership, highlighting the potential to boost the success rates of both companies' development programs. This collaboration also positions Lisata to continue its pioneering work with certainty in the drug development landscape, utilizing GATC’s AI technology to pursue the most efficient studies for the benefit of patients, healthcare providers, and stakeholders.

Traditional drug development is fraught with challenges, often taking over a decade and billions of dollars to bring a single therapy to market. The high failure rate in this sector is largely due to inaccurate target identification and unforeseen complications during clinical trials. GATC’s AI-driven approach is designed to address these issues by providing a more efficient and reliable pathway for drug development.

Jayson Uffens, CTO at GATC, emphasized the value of their validated AI platform in reversing predicted clinical trial failures and providing unbiased analyses of investigational drugs like certepetide. This technology paves the way for a more assured development roadmap, potentially uncovering new indications and intellectual properties related to drug candidates.

Lisata Therapeutics is committed to discovering and developing therapies for life-threatening conditions, with certepetide being a key investigational drug designed to enhance the delivery and efficacy of co-administered anti-cancer agents by targeting solid tumors more effectively. The company has made significant strides in research and partnerships, aiming to announce several milestones within the next eighteen months.

Certepetide, a cyclic peptide, stands out for its potential in improving the delivery of various emerging anti-cancer therapies, including immunotherapies. It has demonstrated safety and clinical activity in trials aimed at enhancing standard chemotherapy for pancreatic cancer. Recognized with multiple designations, including Fast Track and Orphan Drug status, certepetide is poised for further exploration across a range of solid tumors.

GATC Health Corp continues to revolutionize drug development with its proprietary AI platform, which accelerates the discovery of new therapeutics by simulating human biochemistry on a grand scale. This partnership with Lisata marks a significant step in their mission to transform the landscape of drug discovery and development.